SSI Diagnostica (Adelis portfolio) Acquires CTK Biotech

SSI Diagnostica (Adelis) Acquires TECHLAB, Inc. from Pharos Capital

August 22, 2022

Medical Devices

SSI Diagnostica, a portfolio company of Adelis Equity, has acquired TECHLAB, Inc. from Pharos Capital Group. The acquisition combines SSI Diagnostica's global distribution and production capabilities with TECHLAB's U.S. R&D and manufacturing to grow the combined diagnostics business; TECHLAB will continue operating from its Virginia facilities and retain its management team and workforce.

Adelis Equity Partners Becomes Majority Owner of Nordic BioSite Group

May 28, 2021

Healthcare Services

Adelis Equity Partners has acquired a majority stake in Nordic BioSite Group to accelerate the group's growth and pan‑European expansion of its life‑science research and diagnostics distribution platform. Tellacq Partners, together with the founders and management team, had built the group (including Nordic Biosite AB, Sanbio BV and Biomol GmbH); the parties did not disclose the purchase price.

SSI Diagnostica Group Acquires Gulf Coast Scientific

April 28, 2025

Medical Devices

SSI Diagnostica Group (Denmark) has acquired Gulf Coast Scientific, a Florida-based in‑vitro diagnostics company specializing in Urea Breath Testing for Helicobacter pylori. The deal expands SSI Diagnostica Group's gastrointestinal diagnostic portfolio and strengthens its footprint in the US clinical diagnostics market.

Charles River Laboratories Acquires SAMDI Tech

January 30, 2023

Biotechnology

Charles River Laboratories acquired the remaining 80% stake in SAMDI Tech for $50 million in cash, completing a transaction that follows a partnership begun in 2018. The acquisition integrates SAMDI Tech's proprietary mass spectrometry high-throughput screening technology into Charles River's Discovery and Safety Assessment segment to strengthen drug discovery capabilities and accelerate hit identification for pharmaceutical and biotech clients.

Adelis Equity Partners Acquires Majority Stake in IonOpticks

September 10, 2024

Biotechnology

Adelis Equity Partners has taken a majority, controlling stake in IonOpticks, a fast-growing developer and manufacturer of high-performance chromatography solutions for LC‑MS proteomics. The founders and management are co-investors; the investment will fund IonOpticks' global expansion, product development, and support future acquisitions as the company scales its commercial footprint.

TA Associates Makes Strategic Growth Investment in Diatech Pharmacogenetics

April 26, 2023

Biotechnology

TA Associates has signed a definitive agreement to make a strategic growth investment in Diatech Pharmacogenetics, a Jesi, Italy–based developer and manufacturer of molecular diagnostics for precision oncology. Minority investor Alto Partners will fully exit while Diatech's founder and management retain majority ownership; the capital will support product development and international expansion.